Ottawa – January 3, 2024 – Health Canada has authorized Beqvez (fidanacogene elaparvovec), gene therapy for the treatment of hemophilia B. Beqvez is indicated for...
The hemophilia community has been waiting for gene therapy for years; many hoped it would be a cure. Quantitative and qualitative results from late stages...
Ottawa, October 26, 2023 – Health Canada has authorized Hemgenix (etranacogene dezaparvovec), gene therapy for the treatment of hemophilia B. Hemgenix is indicated for the...
The World Federation of Hemophilia SDM Tool is an interactive decision-support system designed to facilitate discussions regarding treatment options between people with hemophilia A or...
Montreal, August 10, 2023 – Gene therapies for hemophilia A and B continue to move closer to becoming reality. Health Canada is currently evaluating two...
